Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 05/18 05:35:23 pm
65.5 EUR   +0.21%
05/10UCB : The comeback of an upward trend can be anticipated
05/08UCB : Proxy Statments
CO
05/03UCB, Science 37 to conduct virtual clinical trials
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

UCB : Acquisition of own shares in the framework of employees’ long-term incentive plans

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/04/2011 | 08:05pm CEST

BRUSSELS, Belgium, 4 August 2011 – 19:30 (CET) – regulated information - In application of art. 207 of the Royal Decree executing the Company Code, UCB publishes having acquired 7,600 UCB shares on the Brussels stock exchange on the dates and at the prices indicated hereunder:

Date

Price EUR

Amount

03/08/2011

31.6376

600

03/08/2011

31.20

2,000

02/08/2011

31.48

2,500

29/07/2011

32.23

500

29/07/2011

32.49

2,000

These shares were immediately distributed to the employees who have exercised share options that had been granted to them in the framework of existing Company’s share option plans of which the detail is given in UCB annual report.

UCB S.A. - Allée de la Recherche, 60 - 1070 Bruxelles - RPM 0403.053.608

For further information [email protected]

Antje Witte, Investor Relations, UCB

T +32.2.559.9414,

[email protected]

Michael Tuck-Sherman, Investor Relations, UCB

T +32.2.559.9712,

About UCB ) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB). www.ucb.com

UCB, Brussels, Belgium (

Forward-looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on UCB
05/08UCB : Proxy Statments
CO
05/03UCB, Science 37 to conduct virtual clinical trials
AQ
04/27UCB : Announces Positive CHMP Opinion for CIMZIA® (certolizumab pegol) in &helli..
PU
04/27UCB : Ex-dividend day for final dividend
FA
04/26UCB : General Meeting of Shareholders
PU
04/25UCB FIRST THREE MONTHS INTERIM REPOR :  UCB tracking …
PU
04/05UCB : Patent Issued for Treatment for Bone Diseases (USPTO 9925260)
AQ
04/04UCB : Transparency notification The Capital Group Companies Inc
AQ
04/04UCB : Acquisition of own shares
AQ
03/23UCB : Convening notice to attend the general meeting of shareholders to be held ..
GL
More news
News from SeekingAlpha
05/17YOUR DAILY PHARMA SCOOP : Loxo Outstanding Results, Cimzia Trial Success, Audent.. 
05/16UCB's Cimzia successful in late-stage study in subtype of ankylosing spondyli.. 
04/27European advisory group April meeting results 
02/23UCB S.A. 2017 Q4 - Results - Earnings Call Slides 
02/22UCB S.A. reports FY results 
Financials (€)
Sales 2018 4 517 M
EBIT 2018 1 107 M
Net income 2018 756 M
Finance 2018 121 M
Yield 2018 1,89%
P/E ratio 2018 16,18
P/E ratio 2019 14,39
EV / Sales 2018 2,79x
EV / Sales 2019 2,60x
Capitalization 12 728 M
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 69,1 €
Spread / Average Target 5,4%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB-1.03%14 981
JOHNSON & JOHNSON-11.36%332 184
PFIZER-1.41%212 424
NOVARTIS-6.55%202 969
ROCHE HOLDING LTD.-8.90%193 622
MERCK AND COMPANY5.10%158 916